Navigation Links
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Date:6/1/2009

9,390 will likely die from the disease.

The ZODIAC, (Zactima in cOmbination with Docetaxel In non-smAll cell lung Cancer) study enrolled 1,391 patients with non-small cell lung cancer from 198 centers between May 2006 and April 2008; all had received chemotherapy previously. Participants were randomized to receive either docetaxel and placebo, or docetaxel and vandetanib. The median follow-up was 12.8 months and the study's primary endpoint was progression-free survival.

Patients in the combination arm had a 21 percent reduction in disease progression, compared to those who received docetaxel alone (hazard ratio, .79), and their median progression-free survival was 17.3 weeks. In contrast, the median progression-free survival in the control arm was 14 weeks. While it trended positive, however, there was no statistical difference in overall survival in the two groups. There was a statistically significant improvement in the time to worsening of symptoms (hazard ratio, .77).

"Obviously, our ultimate goal is to always improve survival for our patients, however the improved time to progression with less of a number of significant effects is important," said Herbst. "This is certainly a drug, where, if we could identify molecular parameters that predict response, we could some day take a group that's receiving docetaxel and vandetanib and see them do even better. We're not there yet, but hopefully this study will serve as the foundation for the merger of personalization and discovery with the now-proven safety and efficacy."

In terms of side effects, patients who received vandetanib experienced more diarrhea, rash and neutropenia. However, they experienced less of the significant side effects - nausea, vomiting, and anemia - than those who received docetaxel alone. The lack of significant side effects is quite striking, said Herbst, because other agents that target VEGF are associated with increased toxicity, including pulmonary blee
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
2. Vaccine shows therapeutic promise against advanced melanoma
3. Study shows gay couples want legal rights, regardless of marriage
4. Immune-Based Lymphoma Treatment Shows Promise
5. Avastin Shows No Benefit Against Early Stage Colon Cancer
6. Study shows drug combination improves outcome for advanced non-small cell lung cancer
7. Tool Shows Promise for Measuring Productivity of Mid-Level Oncology Providers
8. New Study Shows Probiotics Linked to Metabolism
9. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
10. Cottonseed-based drug shows promise in treating severe brain cancer
11. Dementia drugs may put some patients at risk, Queens study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pain does not ... Pain” is a user- and reader-friendly book designed to guide ... to pain-free living. This inspirational book is written to help ... to know a way to regain a pain-free life — ... of chronic pain. , Chronic pain has become an epidemic, ...
(Date:9/22/2014)... 2014) Montefiore Medical Center, Albert Einstein College of Medicine ... received a $300,000 grant from The Agency for Healthcare ... health Information Technology (IT) on patient safety. , This ... important clinical patient safety issue impacted by health IT. ... first time IT leaders have data on the risk ...
Breaking Medicine News(10 mins):Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2Health News:AHRQ grant awarded to study the impact of health IT on patient safety at Montefiore and Einstein and Brigham and Women's Hospital 2
... 23 NxStage Medical, Inc.,(Nasdaq: NXTM ), a ... million private placement of its common stock and,warrants. The ... stock at a price of $4.50 per share and ... an exercise price of $5.50 per share,which price may ...
... 23 Dr. Nancy Minshew, a,leading researcher on the ... work in a presentation co-sponsored by the Pennsylvania,Cyber Charter ... diagnosed with autism. Students with,autism and other special needs ... its mission, is committed to focusing on the needs ...
... University,Medical Center (MUMC) now offers a type of ... the belly button. It,s called single,incision laparoscopic surgery, ... in the SILS technique. One of them is ... remove the gallbladder through a,1cm. incision in the ...
... MDNG, a publication that,reaches nearly a quarter ... discussion that will provide physicians an opportunity,to speak ... unique,practice model has made him a household name. ... 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ., ...
... 500,000 to make a world of difference for Singer Songwriter Katie ... Reider Beginning ... years, Cincinnati-based,singer songwriter Katie Reider, age 29, has inspired the hearts ... within. Fans across the country are banding together to help Katie,during ...
... ... health in the Western world, the, Omega-3 story may someday be viewed ... - William S. Harris, PhD, American ... Nutrition (2003), COLUMBUS, Ohio, May 23 If anyone needed another reason,to ...
Cached Medicine News:Health News:NxStage Announces $43 Million Private Placement of Equity Securities 2Health News:NxStage Announces $43 Million Private Placement of Equity Securities 3Health News:NxStage Announces $43 Million Private Placement of Equity Securities 4Health News:Dr. Nancy Minshew, Autism Researcher, to Speak at Regional Learning Alliance in Cranberry Township 2Health News:SILS Surgical Technique Now Available at MUMC 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 3Health News:Announcing Another Great Reason to Eat Chocolate 2
(Date:9/22/2014)... NEW YORK , September 22, 2014 ... New Market Report on "Global Market Study on Ophthalmic ... Growth by 2020," the global ophthalmic devices market was valued at ... grow at a CAGR of 6.5% from 2014 to ... million in 2020. Browse the full Global Market ...
(Date:9/22/2014)... , Sept. 22, 2014  AVT, Inc. (OTC ... retailing systems and custom vending machines, announced today that ... Unit. This new, smaller sized unit is designed for ... practices. According to industry statistics, there are ... Opticwash is the world,s first automated kiosk ...
(Date:9/22/2014)... GERMANTOWN, Md. , Sept. 22, 2014  Neuralstem, Inc. ... , MD, site investigator at Emory University, presented long-term ... NSI-566 human neural stem cells in the treatment of ... disease).  The presentation, which occurred at the Annual Symposium ... Montreal, Canada , on Friday, and was not ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4
Fixed smooth rod which slides on skin. Designated most popular model or size....
Grooved roller, on which knife oscillates....
Disposable. For use with the N4086....
30 mm button end blade. Flat handle....
Medicine Products: